Skip to content

Bone Metastases in Prostate Cancer

  • Bonomi M
  • Cerchiaro E
  • Villa E
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Bone metastasis and skeletal complications have a devastating impact on the quality of life and are a major cause of morbidity in prostate cancer patients. In addition to established bone-targeted therapies, new drugs such as endothelin A receptor antagonists, MET and VEGFR-2 antagonists or radiopharmaceuticals are in the focus of development. The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (SRE) are bisphosphonates. Denosumab, a human monoclonal antibody against RANKL, appeared to be superior to zoledronic acid for prevention of SRE and has been shown to prolong bone metastases-free survival. In contrast to zoledronic acid, denosumab clearance is not dependent on kidney function and can be administered subcutaneously. Similar rates of toxicity were observed for both substances; however, long-term data for denosumab are limited.

Cite

CITATION STYLE

APA

Bonomi, M., Cerchiaro, E., Villa, E., Setti, L. R., Gianoncelli, L., Micheli, E., & Ceresoli, G. L. (2018). Bone Metastases in Prostate Cancer. In Clinical Applications of Nuclear Medicine Targeted Therapy (pp. 323–343). Springer International Publishing. https://doi.org/10.1007/978-3-319-63067-0_25

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free